Kyverna Therapeutics, Inc. KYTX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s total operating expenses?
- Kyverna Therapeutics, Inc. (KYTX) reported total operating expenses of $41.37M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s total operating expenses changed year-over-year?
- Kyverna Therapeutics, Inc.'s total operating expenses decreased by 12.7% year-over-year, from $47.41M to $41.37M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s total operating expenses?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s total operating expenses has grown at a 65.0% compound annual growth rate (CAGR), from $62.41M to $169.83M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.